Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.